The following is a press release issued by Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics: – First regulatory authorization of a CRISPR-based gene-editing therapy in the world – – CASGEVY is indicated for the treatment of sickle cell disease in patients 12 years of age and older with recurrent vaso-occlusive crises who have the βS/βS, βS/β+ or …
Category: Uncategorized
Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™
The following is a press release issued by Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics: – First regulatory authorization of a CRISPR-based gene-editing therapy in the world – – CASGEVY is indicated for the treatment of sickle cell disease in patients 12 years of age and older with recurrent vaso-occlusive crises who have the βS/βS, βS/β+ or …
Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™
The following is a press release issued by Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics: – First regulatory authorization of a CRISPR-based gene-editing therapy in the world – – CASGEVY is indicated for the treatment of sickle cell disease in patients 12 years of age and older with recurrent vaso-occlusive crises who have the βS/βS, βS/β+ or …